Furthermore, NLRC5 expression was also lower in the “SD+PD” group than in the “PR+CR” group in “Gide et al. Cancer cell 2019” (Figures 11J,K) and “Lauss et al., Nat Commun 2017” (Figure 11L), in which patients receiving anti-PD-1/anti-PD-1+CTLA-4 therapy and adoptive T-cell therapy, respectively. This evidence concerns the gene CTLA4 and cancer.